Company Description
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries.
It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS).
The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company’s BASi product line.
The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts.
The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services.
The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021.
Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
| Country | United States |
| Founded | 1974 |
| IPO Date | Nov 24, 1997 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,055 |
| CEO | Robert W. Leasure Jr. |
Contact Details
Address: 2701 Kent Ave West Lafayette, Indiana 47906-1382 United States | |
| Phone | (317) 463-4527 |
| Website | inotivco.com |
Stock Details
| Ticker Symbol | NOTV |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000720154 |
| CUSIP Number | 45783Q100 |
| ISIN Number | US45783Q1004 |
| Employer ID | 35-1345024 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Robert W. Leasure Jr. | President, Chief Executive Officer and Director |
| Beth A. Taylor CPA | Senior Vice President of Finance and Chief Financial Officer |
| Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D. | Chief Strategy Officer and Director |
| Dr. Peter T. Kissinger | Founder, Chairman Emeritus and Scientific Advisor |
| Brennan Freeman | Vice President of Finance, Principal Accounting Officer and Corporate Controller |
| Andrea Castetter | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Adrian Hardy Ph.D. | Executive Vice President of Global Marketing and Corporate Development |
| Jeffrey Arthur Krupp | Chief Human Resources Officer |
| John Gregory Beattie DSA | Chief Operating Officer of DSA |
| Michael Garrett M.S. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 4, 2024 | 8-K | Current Report |
| May 24, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 24, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 24, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 24, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 24, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 16, 2024 | 10-Q/A | [Amend] Quarterly report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | 8-K | Current Report |
| May 13, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |